Switch to:
Also traded in: Argentina, China, Germany, Hongkong, Mexico, Singapore, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.32
ACH's Cash-to-Debt is ranked lower than
83% of the 1545 Companies
in the Global Aluminum industry.

( Industry Median: 291.20 vs. ACH: 0.32 )
Ranked among companies with meaningful Cash-to-Debt only.
ACH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.26 Max: No Debt
Current: 0.32
Equity-to-Asset 0.20
ACH's Equity-to-Asset is ranked lower than
89% of the 724 Companies
in the Global Aluminum industry.

( Industry Median: 0.60 vs. ACH: 0.20 )
Ranked among companies with meaningful Equity-to-Asset only.
ACH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.38 Max: 0.61
Current: 0.2
0.15
0.61
Interest Coverage 1.73
ACH's Interest Coverage is ranked lower than
93% of the 1021 Companies
in the Global Aluminum industry.

( Industry Median: 10000.00 vs. ACH: 1.73 )
Ranked among companies with meaningful Interest Coverage only.
ACH' s Interest Coverage Range Over the Past 10 Years
Min: 0.98  Med: 1.05 Max: 16.1
Current: 1.73
0.98
16.1
Altman Z-Score: 0.97
WACC vs ROIC
8.65%
8.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % 5.91
ACH's Operating Margin % is ranked higher than
63% of the 743 Companies
in the Global Aluminum industry.

( Industry Median: 1.28 vs. ACH: 5.91 )
Ranked among companies with meaningful Operating Margin % only.
ACH' s Operating Margin % Range Over the Past 10 Years
Min: -4.67  Med: 0.4 Max: 19.57
Current: 5.91
-4.67
19.57
Net Margin % 0.28
ACH's Net Margin % is ranked higher than
50% of the 746 Companies
in the Global Aluminum industry.

( Industry Median: 0.29 vs. ACH: 0.28 )
Ranked among companies with meaningful Net Margin % only.
ACH' s Net Margin % Range Over the Past 10 Years
Min: -11.45  Med: 0.19 Max: 13.45
Current: 0.28
-11.45
13.45
ROE % 1.20
ACH's ROE % is ranked higher than
73% of the 1395 Companies
in the Global Aluminum industry.

( Industry Median: -10.31 vs. ACH: 1.20 )
Ranked among companies with meaningful ROE % only.
ACH' s ROE % Range Over the Past 10 Years
Min: -44.78  Med: 0.45 Max: 20.07
Current: 1.2
-44.78
20.07
ROA % 0.27
ACH's ROA % is ranked higher than
73% of the 1566 Companies
in the Global Aluminum industry.

( Industry Median: -9.58 vs. ACH: 0.27 )
Ranked among companies with meaningful ROA % only.
ACH' s ROA % Range Over the Past 10 Years
Min: -8.29  Med: 0.15 Max: 11.9
Current: 0.27
-8.29
11.9
ROC (Joel Greenblatt) % 7.99
ACH's ROC (Joel Greenblatt) % is ranked higher than
80% of the 1487 Companies
in the Global Aluminum industry.

( Industry Median: -13.76 vs. ACH: 7.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7.98  Med: 3.61 Max: 25.52
Current: 7.99
-7.98
25.52
3-Year Revenue Growth Rate -8.30
ACH's 3-Year Revenue Growth Rate is ranked lower than
61% of the 624 Companies
in the Global Aluminum industry.

( Industry Median: -3.70 vs. ACH: -8.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.3  Med: 14.2 Max: 34.4
Current: -8.3
-8.3
34.4
3-Year EBITDA Growth Rate -5.00
ACH's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 1105 Companies
in the Global Aluminum industry.

( Industry Median: -18.10 vs. ACH: -5.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51  Med: 10.8 Max: 53.9
Current: -5
-51
53.9
3-Year EPS without NRI Growth Rate -29.90
ACH's 3-Year EPS without NRI Growth Rate is ranked lower than
59% of the 990 Companies
in the Global Aluminum industry.

( Industry Median: -20.60 vs. ACH: -29.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -88.4  Med: 12.2 Max: 242
Current: -29.9
-88.4
242
GuruFocus has detected 2 Warning Signs with Aluminum Corporation of China Ltd $ACH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACH's 30-Y Financials

Financials (Next Earnings Date: 2017-08-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ACH Guru Trades in Q2 2016

Jim Simons 265,700 sh (+41.25%)
» More
Q3 2016

ACH Guru Trades in Q3 2016

Jim Simons 358,500 sh (+34.93%)
» More
Q4 2016

ACH Guru Trades in Q4 2016

Jim Simons 460,100 sh (+28.34%)
» More
Q1 2017

ACH Guru Trades in Q1 2017

Jim Simons 508,800 sh (+10.58%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:ACH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Metals & Mining » Aluminum    NAICS: 331313 
Compare:NYSE:AA, OTCPK:NHYDY, OTCPK:AWCMY, NAS:KALU, NAS:CENX, OTCPK:UACJF, NYSE:CSTM, OTCPK:EORBF » details
Traded in other countries:ACH.Argentina, 601600.China, AOCA.Germany, 02600.Hongkong, ACH N.Mexico, K3HD.Singapore, ALMMF.USA,
Headquarter Location:China
Aluminum Corporation of China Ltd is engaged in manufacturing and distribution of alumina, primary aluminum and aluminum fabricated products. It also engaged in the development of bauxite related resources, the production, and fabrication.

The Aluminum Corporation of China, or Chalco, is one of the world's leading aluminum producers. The company competes across every phase of upstream aluminum production--bauxite mining, alumina refining, and primary aluminum smelting. Chalco almost exclusively serves the domestic market and is a high-cost producer relative to other major industry players around the globe.

Top Ranked Articles about Aluminum Corporation of China Ltd

Synthesis Energy Systems, Inc. Announces China Joint Venture Partner, Suzhou THVOW Technology Company, Reports Initial Start-Up of Aluminum Corporation of China 4-System Industrial Syngas Facility – Largest Capacity SES Gasification Technology Projec
6 Companies That Beat the S&P 500 Index Stocks with great returns over the last 12 months
The following are some of the stocks that outperformed the Standard & Poor's 500 Index over the last 12 months and were bought by gurus during the last quarter. Read more...
Arch "Borg" Peptide Coating Displays Anti Corrosion Performance on Stainless Steel

TORONTO, ONTARIO--(Marketwired - Jul 5, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced that scientists at a corrosion research laboratory have confirmed that Arch's 'Borg' peptides display significant anti-corrosion performance on stainless steel.
Dr. Frank Cheng and his team at the Corrosion, Pipeline Integrity and Advanced Material Technology Laboratory at the University of Calgary recently tested the Arch peptide coating technology invented by Arch scientist Dr. Randall Irvin at the University of Alberta. Researchers found that the most effective of the Arch Borg peptides reduce corrosion on 304 stainless steel by up to 85% in electrolyte solution.
Details of their findings have been accepted for publication by the journal Materials Science and Engineering C: Materials for Biological Applications. The publication titled "Peptide-based biocoatings for corrosion protection of stainless steel biomaterial in chloride solutions" by Muruve et al can be found at http://www.sciencedirect.com/science/article/pii/S0928493116306221 until it is assigned to the November 2016 issue of the journal.
Increasing corrosion resistance of stainless steel and other alloys has potential benefit in numerous applications, particularly in the medical implant and device sectors. Due to prolonged contact with physiologic fluids, metallic biomedical implants are susceptible to corrosion which can contribute to adverse effects in patients and/or device failure. Arch's development of the Borg peptide coatings for these sectors is ongoing. About Arch Biopartners Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors. Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets elusive brain tumor initiating cells; Metablok, a potential treatment for sepsis and cancer metastasis; and, 'Borg' peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics. For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com. The Company currently has 53,849,679 common shares outstanding. Forward-Looking Statements All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Arch Biopartners Inc.
Andrew Bishop
Director
647-428-7031
[email protected]
www.archbiopartners.com
Virtus Advisory Group Inc.
Babak Pedram
Investor Relations
416-644-5081
[email protected]




Read more...
Arch Biopartners Closes First Tranche of Private Placement

TORONTO, ONTARIO--(Marketwired - Jun 23, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has raised $330,000 by closing the first tranche of the non-brokered private placement it announced in a press release June 14, 2016 (The "Offering"). Pursuant to the terms of the Offering, Arch issued 660,000 Units at a price of $0.50 per unit (the "Units"). Each Unit consists of one common share of the Company and one common share purchase warrant (the "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.50 per common share for until 5:00PM EST on June 22, 2018. Arch received Conditional Acceptance from the TSX Venture Exchange for this private placement on June 20, 2016. All securities issued in connection with this offering will be subject to a statutory hold period expiring on October 23, 2016. Finder's fees paid in connection with the first tranche of the Offering totalled $2,500 plus 5,500 broker warrants with the same terms as the Warrants. The Company intends to use the proceeds from the Offering to initiate chemistry, manufacturing and controls for its drug candidate, AB569, to enable future human trials testing the drug's efficacy in treating antibiotic resistant lung and urinary tract infections. The Offering is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including Final Approval of the TSXV before July 29, 2016. Management of the Company expects a second tranche of up to $70,000 to close on or before the date of Final Approval, pursuant to the terms of the first tranche described herein. There is no material fact or material change about the Company that has not been generally disclosed. About Arch Biopartners Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors. Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets elusive brain tumor initiating cells; and, Metablok, a potential treatment for sepsis and cancer metastasis. For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com. The Company now has 53,849,679 common shares outstanding. Forward-Looking Statements All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Arch Biopartners, Inc.
Richard Muruve
Chief Executive Officer
647-428-7031
[email protected]
www.archbiopartners.com
Virtus Advisory Group Inc.
Babak Pedram
Investor Relations
416-644-5081
[email protected]




Read more...
Arch Biopartners Announces Non Brokered Private Placement Financing

TORONTO, ONTARIO--(Marketwired - Jun 14, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to complete a non-brokered private placement offering of up to 800,000 units priced at $0.50 per unit (the "Units") for gross proceeds of up to $400,000 (the "Offering"). Each Unit will consist of one common share of the Company and one common share purchase warrant (the "Warrant"). Each Warrant will entitle the holder thereof to acquire one common share of the Company at an exercise price of $0.50 per common share for a period of 24 months from the closing date of the Offering. All securities issued in connection with the Offering will be subject to a hold period of four months and one day from the closing date.
A portion or all of the Offering may be completed pursuant to Multilateral CSA Notice 45-318 - Prospectus Exemption for Certain Distributions through an Investment Dealer ("CSA 45-318") and the corresponding blanket orders and rules implementing CSA 45-318 in the participating jurisdictions in respect thereof (collectively with CSA 45-318, the "Investment Dealer Exemption"). In order for the Company to be able to rely on the Investment Dealer Exemption, each subscriber must purchase the shares as principal and obtain advice regarding the suitability of the investment from a person that is registered as an investment dealer in the jurisdiction in which the subscriber is a resident. The Company intends to use the proceeds from the private placement for the chemistry, manufacturing and controls of its drug candidate, AB569, to enable future human trials to test the drug's efficacy in treating antibiotic resistant infections. The Offering is expected to close on or about June 20th, 2016 and is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including approval of the TSXV as well as the satisfaction of other customary closing conditions. Finder's fees may be paid in connection with the Offering. There is no material fact or material change about the Company that has not been generally disclosed. About Arch Biopartners Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors. Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets elusive brain tumor initiating cells; and, Metablok, a potential treatment for sepsis and cancer metastasis. For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com The Company has 53,189,679 common shares outstanding. Forward-Looking Statements All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Arch Biopartners Inc.
Richard Muruve
Chief Executive Officer
647-428-7031
[email protected]
www.archbiopartners.com
Virtus Advisory Group Inc.
Babak Pedram
Investor Relations
416-644-5081
[email protected]




Read more...
Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis

TORONTO, ONTARIO--(Marketwired - Jun 1, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced the European Commission has designated AB569 as an orphan medicinal product in the European Union for the treatment of patients with cystic fibrosis (CF).
The orphan medicinal products designation is for the two active ingredients of AB569, sodium nitrite ethylenediaminetetraacetic acid (EDTA). AB569 was developed to treat antibiotic resistant bacterial infections, which is a significant problem in the lungs of most adult CF patients. About Arch Biopartners Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors. Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets illusive brain tumor initiating cells; and, Metablok, a potential treatment for sepsis and cancer metastasis. For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com The Company has 53,189,679 common shares outstanding. Forward-Looking Statements All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.





Arch Biopartners Inc.
Richard Muruve
Chief Executive Officer
647-428-7031
[email protected]
www.archbiopartners.com
Virtus Advisory Group Inc.
Babak Pedram
Investor Relations
416-644-5081
[email protected]




Read more...

Ratios

vs
industry
vs
history
PE Ratio 209.15
ACH's PE Ratio is ranked lower than
96% of the 450 Companies
in the Global Aluminum industry.

( Industry Median: 19.78 vs. ACH: 209.15 )
Ranked among companies with meaningful PE Ratio only.
ACH' s PE Ratio Range Over the Past 10 Years
Min: 4.75  Med: 29.51 Max: 2300
Current: 209.15
4.75
2300
Forward PE Ratio 16.53
ACH's Forward PE Ratio is ranked higher than
51% of the 583 Companies
in the Global Aluminum industry.

( Industry Median: 17.01 vs. ACH: 16.53 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 139.48
ACH's PE Ratio without NRI is ranked lower than
93% of the 443 Companies
in the Global Aluminum industry.

( Industry Median: 20.29 vs. ACH: 139.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
ACH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.76  Med: 29.37 Max: 863.33
Current: 139.48
4.76
863.33
PB Ratio 1.65
ACH's PB Ratio is ranked higher than
56% of the 1388 Companies
in the Global Aluminum industry.

( Industry Median: 2.03 vs. ACH: 1.65 )
Ranked among companies with meaningful PB Ratio only.
ACH' s PB Ratio Range Over the Past 10 Years
Min: 1.4  Med: 2.38 Max: 12.81
Current: 1.65
1.4
12.81
PS Ratio 0.53
ACH's PS Ratio is ranked higher than
80% of the 672 Companies
in the Global Aluminum industry.

( Industry Median: 1.84 vs. ACH: 0.53 )
Ranked among companies with meaningful PS Ratio only.
ACH' s PS Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.74 Max: 9.36
Current: 0.53
0.52
9.36
Price-to-Free-Cash-Flow 16.99
ACH's Price-to-Free-Cash-Flow is ranked lower than
55% of the 237 Companies
in the Global Aluminum industry.

( Industry Median: 17.07 vs. ACH: 16.99 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.8  Med: 20.27 Max: 48.94
Current: 16.99
16.8
48.94
Price-to-Operating-Cash-Flow 8.56
ACH's Price-to-Operating-Cash-Flow is ranked lower than
51% of the 385 Companies
in the Global Aluminum industry.

( Industry Median: 8.68 vs. ACH: 8.56 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.46  Med: 48.41 Max: 139.29
Current: 8.56
8.46
139.29
EV-to-EBIT 22.74
ACH's EV-to-EBIT is ranked lower than
58% of the 904 Companies
in the Global Aluminum industry.

( Industry Median: 20.02 vs. ACH: 22.74 )
Ranked among companies with meaningful EV-to-EBIT only.
ACH' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 21.3 Max: 850.5
Current: 22.74
5.9
850.5
EV-to-EBITDA 14.93
ACH's EV-to-EBITDA is ranked lower than
64% of the 971 Companies
in the Global Aluminum industry.

( Industry Median: 10.14 vs. ACH: 14.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9  Med: 19.9 Max: 850.5
Current: 14.93
5.9
850.5
Shiller PE Ratio 8.45
ACH's Shiller PE Ratio is ranked higher than
82% of the 183 Companies
in the Global Aluminum industry.

( Industry Median: 24.05 vs. ACH: 8.45 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACH' s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.37  Med: 8.87 Max: 10.98
Current: 8.45
7.37
10.98
Current Ratio 0.80
ACH's Current Ratio is ranked lower than
76% of the 1502 Companies
in the Global Aluminum industry.

( Industry Median: 2.17 vs. ACH: 0.80 )
Ranked among companies with meaningful Current Ratio only.
ACH' s Current Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.82 Max: 1.39
Current: 0.8
0.58
1.39
Quick Ratio 0.58
ACH's Quick Ratio is ranked lower than
75% of the 1502 Companies
in the Global Aluminum industry.

( Industry Median: 1.71 vs. ACH: 0.58 )
Ranked among companies with meaningful Quick Ratio only.
ACH' s Quick Ratio Range Over the Past 10 Years
Min: 0.28  Med: 0.51 Max: 0.77
Current: 0.58
0.28
0.77
Days Inventory 41.17
ACH's Days Inventory is ranked higher than
75% of the 606 Companies
in the Global Aluminum industry.

( Industry Median: 76.92 vs. ACH: 41.17 )
Ranked among companies with meaningful Days Inventory only.
ACH' s Days Inventory Range Over the Past 10 Years
Min: 41.17  Med: 64.36 Max: 106.39
Current: 41.17
41.17
106.39
Days Sales Outstanding 10.55
ACH's Days Sales Outstanding is ranked higher than
77% of the 600 Companies
in the Global Aluminum industry.

( Industry Median: 36.83 vs. ACH: 10.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.76  Med: 8.15 Max: 11.46
Current: 10.55
2.76
11.46
Days Payable 21.86
ACH's Days Payable is ranked lower than
79% of the 464 Companies
in the Global Aluminum industry.

( Industry Median: 47.37 vs. ACH: 21.86 )
Ranked among companies with meaningful Days Payable only.
ACH' s Days Payable Range Over the Past 10 Years
Min: 12.43  Med: 21.01 Max: 27.14
Current: 21.86
12.43
27.14

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.30
ACH's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 1131 Companies
in the Global Aluminum industry.

( Industry Median: -12.90 vs. ACH: -3.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10  Med: -2.75 Max: 0
Current: -3.3
-10
0

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 2.58
ACH's Price-to-Tangible-Book is ranked lower than
57% of the 1342 Companies
in the Global Aluminum industry.

( Industry Median: 2.29 vs. ACH: 2.58 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.5  Med: 4.31 Max: 22.21
Current: 2.58
1.5
22.21
Price-to-Intrinsic-Value-Projected-FCF 2.52
ACH's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 325 Companies
in the Global Aluminum industry.

( Industry Median: 2.03 vs. ACH: 2.52 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.92  Med: 3.45 Max: 10.62
Current: 2.52
1.92
10.62
Price-to-Median-PS-Value 0.20
ACH's Price-to-Median-PS-Value is ranked higher than
95% of the 518 Companies
in the Global Aluminum industry.

( Industry Median: 1.05 vs. ACH: 0.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 1.29 Max: 3.04
Current: 0.2
0.19
3.04
Price-to-Graham-Number 3.87
ACH's Price-to-Graham-Number is ranked lower than
92% of the 368 Companies
in the Global Aluminum industry.

( Industry Median: 1.43 vs. ACH: 3.87 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ACH' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.71  Med: 4.5 Max: 20.5
Current: 3.87
1.71
20.5
Earnings Yield (Greenblatt) % 4.38
ACH's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 1748 Companies
in the Global Aluminum industry.

( Industry Median: -0.10 vs. ACH: 4.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 4.7 Max: 16.8
Current: 4.38
0.1
16.8
Forward Rate of Return (Yacktman) % 41.02
ACH's Forward Rate of Return (Yacktman) % is ranked higher than
93% of the 305 Companies
in the Global Aluminum industry.

( Industry Median: -2.06 vs. ACH: 41.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACH' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -18.9  Med: 42.7 Max: 64.3
Current: 41.02
-18.9
64.3

More Statistics

Revenue (TTM) (Mil) $21,493
EPS (TTM) $ 0.08
Beta0.23
Short Percentage of Float0.00%
52-Week Range $7.22 - 13.85
Shares Outstanding (Mil)596.15

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 23,934 25,113
EPS ($) 0.69 0.22
EPS without NRI ($) 0.69 0.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.45%
Dividends per Share ($)
» More Articles for NYSE:ACH

Headlines

Articles On GuruFocus.com
Synthesis Energy Systems, Inc. Announces China Joint Venture Partner, Suzhou THVOW Technology Compan Apr 12 2017 
7 Stocks That Are Outperforming the Market Mar 22 2017 
6 Companies That Beat the S&P 500 Index Jan 05 2017 
Arch "Borg" Peptide Coating Displays Anti Corrosion Performance on Stainless Steel Jul 05 2016 
Arch Biopartners Closes First Tranche of Private Placement Jun 23 2016 
Arch Biopartners Announces Non Brokered Private Placement Financing Jun 14 2016 
Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Jun 01 2016 
Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fi Apr 26 2016 
Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569 Mar 16 2016 
Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569 Mar 01 2016 

More From Other Websites
Analyzing China’s Aluminum Production Data May 24 2017
ETFs with exposure to Aluminum Corp. of China Ltd. : May 1, 2017 May 01 2017
Aluminum Corp. of China Ltd. :ACH-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 Apr 28 2017
What Investors Should Know about Century Aluminum’s 1Q17 Results Apr 26 2017
Synthesis Energy Systems, Inc. Announces China Joint Venture Partner, Suzhou THVOW Technology... Apr 12 2017
ETFs with exposure to Aluminum Corp. of China Ltd. : April 7, 2017 Apr 07 2017
7 Stocks Beating the Market Apr 05 2017
Aluminum Corp. of China Ltd. :ACH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017 Mar 28 2017
7 Stocks That Are Outperforming the Market Mar 22 2017
ETFs with exposure to Aluminum Corp. of China Ltd. : January 25, 2017 Jan 25 2017
6 Companies That Beat the S&P 500 Index Jan 05 2017
What Could Trump’s Presidency Mean for Alcoa and Aluminum? Dec 16 2016
What to Expect from Chinese Aluminum Demand Next Year Dec 16 2016
What Do China’s Aluminum Demand Indicators Suggest? Dec 15 2016
What Do China’s Demand Indicators Mean for Alcoa Stock? Nov 28 2016
Aluminum Corp. of China Ltd. :ACH-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016 Nov 15 2016
Could Trump’s Policies Revive Alcoa and Aluminum Markets? Nov 14 2016
Can Higher Chinese Aluminum Exports Spoil Alcoa’s Party? Nov 09 2016
Chalco Swings to Profit as Sales Surges Amid Price Rebound Oct 20 2016
ETF’s with exposure to Aluminum Corp. of China Ltd. : October 11, 2016 Oct 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat